Insight into the Mechanisms of Cocrystallization of Pharmaceuticals in Supercritical Solvents

Carbon dioxide has been extensively used as a green solvent medium for the crystallization of active pharmaceutical ingredients (APIs) by replacing harmful organic solvents. This work explores the mechanisms underlying a novel recrystallization methodcocrystallization with supercritical solvent (CS...

Full description

Saved in:
Bibliographic Details
Published in:Crystal growth & design Vol. 15; no. 7; pp. 3175 - 3181
Main Authors: Padrela, Luis, Rodrigues, Miguel A, Tiago, João, Velaga, Sitaram P, Matos, Henrique A, de Azevedo, Edmundo Gomes
Format: Journal Article
Language:English
Published: American Chemical Society 01-07-2015
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Carbon dioxide has been extensively used as a green solvent medium for the crystallization of active pharmaceutical ingredients (APIs) by replacing harmful organic solvents. This work explores the mechanisms underlying a novel recrystallization methodcocrystallization with supercritical solvent (CSS)which enables APIs cocrystallization by suspending powders in pure CO2. Six well-known APIs that form cocrystals with saccharin (SAC) were processed by CSS, namely, theophylline (TPL), indomethacin (IND), carbamazepine (CBZ), caffeine (CAF), sulfamethazine (SFZ), and acetylsalicylic acid (ASA). Pure cocrystals were obtained for TPL, IND, and CBZ (with SAC) after 2 h of CSS processing. Convection was revealed to be a determining parameter for successful cocrystallization with high-yield levels. TPL–SAC was selected as a model system to study the cocrystallization kinetics in the gas, supercritical, and liquid phases under different conditions of pressure (8–20 MPa), temperature (30 to 70 °C), and convection regimes. The solubility of each substance in CO2 was measured at the selected working conditions. TPL–SAC showed a cocrystallization rate of 2.9% min–1, two times higher than that of IND–SAC, due to the higher solubility of TPL in CO2. The cocrystallization kinetics was also improved by increasing the CO2 density, showing that cocrystallization was limited by the dissolution of cocrystal formers. Overall, the CSS process has a potential for scale-up as a novel, simple, solvent-free batch process whenever the cocrystal phase is formed in the CO2 media.
AbstractList Carbon dioxide has been extensively used as a green solvent medium for the crystallization of active pharmaceutical ingredients (APIs) by replacing harmful organic solvents. This work explores the mechanisms underlying a novel recrystallization methodcocrystallization with supercritical solvent (CSS)which enables APIs cocrystallization by suspending powders in pure CO2. Six well-known APIs that form cocrystals with saccharin (SAC) were processed by CSS, namely, theophylline (TPL), indomethacin (IND), carbamazepine (CBZ), caffeine (CAF), sulfamethazine (SFZ), and acetylsalicylic acid (ASA). Pure cocrystals were obtained for TPL, IND, and CBZ (with SAC) after 2 h of CSS processing. Convection was revealed to be a determining parameter for successful cocrystallization with high-yield levels. TPL–SAC was selected as a model system to study the cocrystallization kinetics in the gas, supercritical, and liquid phases under different conditions of pressure (8–20 MPa), temperature (30 to 70 °C), and convection regimes. The solubility of each substance in CO2 was measured at the selected working conditions. TPL–SAC showed a cocrystallization rate of 2.9% min–1, two times higher than that of IND–SAC, due to the higher solubility of TPL in CO2. The cocrystallization kinetics was also improved by increasing the CO2 density, showing that cocrystallization was limited by the dissolution of cocrystal formers. Overall, the CSS process has a potential for scale-up as a novel, simple, solvent-free batch process whenever the cocrystal phase is formed in the CO2 media.
Carbon dioxide has been extensively used as a green solvent medium for the crystallization of active pharmaceutical ingredients (APIs) by replacing harmful organic solvents. This work explores the mechanisms underlying a novel recrystallization method-cocrystallization with supercritical solvent (CSS)-which enables APIs cocrystallization by suspending powders in pure CO2. Six well-known APIs that form cocrystals with saccharin (SAC) were processed by CSS, namely, theophylline (TPL), indomethacin (IND), carbamazepine (CBZ), caffeine (CAF), sulfamethazine (SFZ), and acetylsalicylic acid (ASA). Pure cocrystals were obtained for TPL, IND, and CBZ (with SAC) after 2 h of CSS processing. Convection was revealed to be a determining parameter for successful cocrystallization with high-yield levels. TPL-SAC was selected as a model system to study the cocrystallization kinetics in the gas, supercritical, and liquid phases under different conditions of pressure (8-20 MPa), temperature (30 to 70 degrees C), and convection regimes. The solubility of each substance in CO2 was measured at the selected working conditions. TPL-SAC showed a cocrystallization rate of 2.9% min(-1), two times higher than that of IND-SAC, due to the higher solubility of TPL in CO2. The cocrystallization kinetics was also improved by increasing the CO2 density, showing that cocrystallization was limited by the dissolution of cocrystal formers. Overall, the CSS process has a potential for scale-up as a novel, simple, solvent-free batch process whenever the cocrystal phase is formed in the CO2 media.
Author Padrela, Luis
Tiago, João
Velaga, Sitaram P
de Azevedo, Edmundo Gomes
Matos, Henrique A
Rodrigues, Miguel A
AuthorAffiliation Centro de Química Estrutural and Department of Chemical Engineering, Instituto Superior Técnico
Department of Health Sciences
Universidade de Lisboa
Luleå University of Technology
AuthorAffiliation_xml – name: Luleå University of Technology
– name: Centro de Química Estrutural and Department of Chemical Engineering, Instituto Superior Técnico
– name: Universidade de Lisboa
– name: Department of Health Sciences
Author_xml – sequence: 1
  givenname: Luis
  surname: Padrela
  fullname: Padrela, Luis
– sequence: 2
  givenname: Miguel A
  surname: Rodrigues
  fullname: Rodrigues, Miguel A
  email: miguelrodrigues@tecnico.ulisboa.pt
– sequence: 3
  givenname: João
  surname: Tiago
  fullname: Tiago, João
– sequence: 4
  givenname: Sitaram P
  surname: Velaga
  fullname: Velaga, Sitaram P
– sequence: 5
  givenname: Henrique A
  surname: Matos
  fullname: Matos, Henrique A
– sequence: 6
  givenname: Edmundo Gomes
  surname: de Azevedo
  fullname: de Azevedo, Edmundo Gomes
BackLink https://urn.kb.se/resolve?urn=urn:nbn:se:ltu:diva-14547$$DView record from Swedish Publication Index
BookMark eNp1kN9PwjAQxxuDiYA--7p33Wi3jm6PBH-RYDRBfTPNtXSsZLSk7TT41zsEffPpLnefzyX3HaCesUYhdElwQnBKRiB9IlfLJBcYpxifoD7J0yJmOc57vz0tsjM08H6NMWbjLOuj95nxelWHSJtgo1Cr6FHJGoz2Gx_ZKppa6XY-QNPoLwjamv3wuQa3AanaoCU0vnOjRbtVTjr9M4kWtvlQJvhzdFp1gLo41iF6vbt9mT7E86f72XQyjyEjNMSVqlTBQKaqBCFASArLgooiLRmGZU4VY6XMRMVSnFVYUjIGVaaiJHkhygJkNkTXh7v-U21bwbdOb8DtuAXNb_TbhFu34k1oOaE5ZR0-OuDSWe-dqv4Egvk-TN6Fybsw-THMzrg6GPvF2rbOdO_8S38DQCJ8gQ
CitedBy_id crossref_primary_10_1016_j_supflu_2020_105134
crossref_primary_10_1021_acs_cgd_6b00697
crossref_primary_10_3390_pharmaceutics13060898
crossref_primary_10_1016_j_supflu_2023_105976
crossref_primary_10_1016_j_supflu_2023_106029
crossref_primary_10_1016_j_tifs_2021_01_035
crossref_primary_10_1021_acs_cgd_0c00571
crossref_primary_10_1016_j_supflu_2023_106022
crossref_primary_10_1016_j_supflu_2023_105990
crossref_primary_10_1021_acs_cgd_0c01427
crossref_primary_10_1021_acs_cgd_8b00385
crossref_primary_10_1021_acs_cgd_8b01034
crossref_primary_10_1002_slct_202202588
crossref_primary_10_1016_j_indcrop_2019_111537
crossref_primary_10_1021_acs_cgd_8b01015
crossref_primary_10_3390_pharmaceutics11120629
crossref_primary_10_1016_j_supflu_2021_105190
crossref_primary_10_1016_j_supflu_2020_104813
crossref_primary_10_1021_acs_oprd_9b00545
crossref_primary_10_22159_ijcpr_2022v14i5_2038
crossref_primary_10_1016_j_molliq_2021_116117
crossref_primary_10_3389_fphar_2021_780582
crossref_primary_10_3390_cryst10090760
crossref_primary_10_1021_acsapm_1c01626
crossref_primary_10_1016_j_supflu_2018_11_014
crossref_primary_10_1016_j_addr_2018_07_010
crossref_primary_10_1016_j_supflu_2019_104564
crossref_primary_10_1021_acs_cgd_5b01809
crossref_primary_10_1134_S0022476618050268
crossref_primary_10_3390_cryst11030303
crossref_primary_10_1016_j_supflu_2018_02_004
crossref_primary_10_1016_j_addr_2017_07_008
crossref_primary_10_1016_j_cej_2016_05_129
crossref_primary_10_1021_acs_cgd_8b00933
crossref_primary_10_1039_C6RA10917A
crossref_primary_10_1021_acs_cgd_2c01553
crossref_primary_10_1016_j_addr_2017_08_006
crossref_primary_10_1021_acs_cgd_1c00418
crossref_primary_10_1039_D0MD00400F
crossref_primary_10_1016_j_ejps_2019_104971
Cites_doi 10.1016/j.supflu.2010.01.010
10.1111/j.2042-7158.2010.01189.x
10.1021/cg060327x
10.1016/j.supflu.2011.05.012
10.1021/cg401131x
10.1016/j.drudis.2008.03.004
10.1039/9781849733502-00247
10.1016/j.supflu.2011.03.002
10.1021/cg900003m
10.1021/cg900129f
10.1016/j.ejps.2009.05.010
10.1007/s11095-007-9394-1
10.1016/S0928-0987(01)00115-4
10.3109/03639045.2011.633263
10.1007/s11095-006-9032-3
10.1021/cg800936d
10.1002/jps.21962
10.1039/b801713c
10.1038/nchem.1256
10.1016/j.supflu.2006.08.008
10.1021/cg034212u
10.1021/cg060834e
10.1039/b402150a
10.1021/cg034172u
10.1016/0378-3812(94)80070-7
10.1021/cg800764n
ContentType Journal Article
Copyright Copyright © American Chemical Society
Copyright_xml – notice: Copyright © American Chemical Society
DBID AAYXX
CITATION
ADTPV
AOWAS
DOI 10.1021/acs.cgd.5b00200
DatabaseName CrossRef
SwePub
SwePub Articles
DatabaseTitle CrossRef
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
Discipline Engineering
Chemistry
EISSN 1528-7505
EndPage 3181
ExternalDocumentID oai_DiVA_org_ltu_14547
10_1021_acs_cgd_5b00200
c687420837
GroupedDBID 4.4
55A
5GY
5VS
7~N
AABXI
ABMVS
ABPTK
ABUCX
ACGFS
ACS
AEESW
AENEX
AFEFF
AFFNX
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAANH
CS3
DU5
EBS
ED
ED~
EJD
F5P
GNL
IH9
IHE
JG
JG~
LG6
P2P
RNS
ROL
TN5
UI2
VF5
VG9
W1F
X
-~X
6J9
AAYXX
ABJNI
ABQRX
ADHLV
AHGAQ
CITATION
CUPRZ
GGK
ADTPV
AOWAS
ID FETCH-LOGICAL-a314t-fefe87ac2e9abbabc4ad84b82970ad54e779c3bf7203f0c416ae92b9158b98ac3
IEDL.DBID ACS
ISSN 1528-7483
1528-7505
IngestDate Sat Aug 24 00:47:59 EDT 2024
Fri Aug 23 03:21:53 EDT 2024
Thu Aug 27 13:51:23 EDT 2020
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a314t-fefe87ac2e9abbabc4ad84b82970ad54e779c3bf7203f0c416ae92b9158b98ac3
PageCount 7
ParticipantIDs swepub_primary_oai_DiVA_org_ltu_14547
crossref_primary_10_1021_acs_cgd_5b00200
acs_journals_10_1021_acs_cgd_5b00200
ProviderPackageCode JG~
55A
AABXI
GNL
VF5
7~N
VG9
W1F
ACS
AEESW
AFEFF
ABMVS
ABUCX
IH9
BAANH
AQSVZ
ED~
UI2
PublicationCentury 2000
PublicationDate 2015-07-01
PublicationDateYYYYMMDD 2015-07-01
PublicationDate_xml – month: 07
  year: 2015
  text: 2015-07-01
  day: 01
PublicationDecade 2010
PublicationTitle Crystal growth & design
PublicationTitleAlternate Cryst. Growth Des
PublicationYear 2015
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References Padrela L. (ref25/cit25) 2012; 38
Bettini R (ref14/cit14) 2009; 99
Bouchard A. (ref17/cit17) 2007; 7
Shan N. (ref7/cit7) 2008; 13
Padrela L. (ref20/cit20) 2009; 38
Padrela L. (ref21/cit21) 2010; 53
Tiago J. M. (ref22/cit22) 2013; 13
McNamara D. P. (ref5/cit5) 2006; 23
Wuest J. D. (ref6/cit6) 2012; 4
ref23/cit23
Miroshnyk I. (ref9/cit9) 2009; 6
Mazzotti M. (ref13/cit13) 2004; 4
Basavoju S. (ref2/cit2) 2008; 25
Almarsson Ö. (ref1/cit1) 2004; 17
Johannsen M. (ref26/cit26) 1994; 95
ref28/cit28
Basavoju S. (ref3/cit3) 2006; 6
Bettini R. (ref15/cit15) 2001; 13
Lu E. (ref24/cit24) 2008; 10
Rodrigues M. (ref18/cit18) 2011; 58
Schultheiss N. (ref8/cit8) 2009; 9
Diankov S. (ref29/cit29) 2007; 41
Min-Sook J. (ref4/cit4) 2010; 62
Weyna D. R. (ref10/cit10) 2009; 9
Uchida H. (ref12/cit12) 2004; 4
Friščić T. (ref11/cit11) 2009; 9
Martín Á. (ref16/cit16) 2009; 9
Roy C. (ref19/cit19) 2011; 57
References_xml – volume: 53
  start-page: 156
  year: 2010
  ident: ref21/cit21
  publication-title: J. Supercrit. Fluids
  doi: 10.1016/j.supflu.2010.01.010
  contributor:
    fullname: Padrela L.
– volume: 62
  start-page: 1560
  year: 2010
  ident: ref4/cit4
  publication-title: J. Pharm. Pharmacol.
  doi: 10.1111/j.2042-7158.2010.01189.x
  contributor:
    fullname: Min-Sook J.
– volume: 6
  start-page: 2699
  year: 2006
  ident: ref3/cit3
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg060327x
  contributor:
    fullname: Basavoju S.
– volume: 58
  start-page: 303
  year: 2011
  ident: ref18/cit18
  publication-title: J. Supercrit. Fluids
  doi: 10.1016/j.supflu.2011.05.012
  contributor:
    fullname: Rodrigues M.
– volume: 13
  start-page: 4940
  year: 2013
  ident: ref22/cit22
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg401131x
  contributor:
    fullname: Tiago J. M.
– volume: 13
  start-page: 440
  year: 2008
  ident: ref7/cit7
  publication-title: Drug Discovery Today
  doi: 10.1016/j.drudis.2008.03.004
  contributor:
    fullname: Shan N.
– ident: ref28/cit28
  doi: 10.1039/9781849733502-00247
– volume: 57
  start-page: 267
  year: 2011
  ident: ref19/cit19
  publication-title: J. Supercrit. Fluids
  doi: 10.1016/j.supflu.2011.03.002
  contributor:
    fullname: Roy C.
– volume: 9
  start-page: 2504
  year: 2009
  ident: ref16/cit16
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg900003m
  contributor:
    fullname: Martín Á.
– volume: 9
  start-page: 2950
  year: 2009
  ident: ref8/cit8
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg900129f
  contributor:
    fullname: Schultheiss N.
– volume: 38
  start-page: 9
  year: 2009
  ident: ref20/cit20
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2009.05.010
  contributor:
    fullname: Padrela L.
– volume: 25
  start-page: 530
  year: 2008
  ident: ref2/cit2
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-007-9394-1
  contributor:
    fullname: Basavoju S.
– volume: 13
  start-page: 281
  year: 2001
  ident: ref15/cit15
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/S0928-0987(01)00115-4
  contributor:
    fullname: Bettini R.
– ident: ref23/cit23
– volume: 38
  start-page: 923
  year: 2012
  ident: ref25/cit25
  publication-title: Drug Dev. Ind. Pharm.
  doi: 10.3109/03639045.2011.633263
  contributor:
    fullname: Padrela L.
– volume: 23
  start-page: 1888
  year: 2006
  ident: ref5/cit5
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-006-9032-3
  contributor:
    fullname: McNamara D. P.
– volume: 9
  start-page: 1106
  year: 2009
  ident: ref10/cit10
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg800936d
  contributor:
    fullname: Weyna D. R.
– volume: 99
  start-page: 1855
  year: 2009
  ident: ref14/cit14
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.21962
  contributor:
    fullname: Bettini R
– volume: 10
  start-page: 665
  year: 2008
  ident: ref24/cit24
  publication-title: CrystEngComm
  doi: 10.1039/b801713c
  contributor:
    fullname: Lu E.
– volume: 4
  start-page: 74
  year: 2012
  ident: ref6/cit6
  publication-title: Nature Chem.
  doi: 10.1038/nchem.1256
  contributor:
    fullname: Wuest J. D.
– volume: 6
  start-page: 333
  year: 2009
  ident: ref9/cit9
  publication-title: Adv. Drug Delivery Rev.
  contributor:
    fullname: Miroshnyk I.
– volume: 41
  start-page: 164
  year: 2007
  ident: ref29/cit29
  publication-title: J. Supercrit. Fluids
  doi: 10.1016/j.supflu.2006.08.008
  contributor:
    fullname: Diankov S.
– volume: 4
  start-page: 937
  year: 2004
  ident: ref12/cit12
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg034212u
  contributor:
    fullname: Uchida H.
– volume: 7
  start-page: 1432
  year: 2007
  ident: ref17/cit17
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg060834e
  contributor:
    fullname: Bouchard A.
– volume: 17
  start-page: 1889
  year: 2004
  ident: ref1/cit1
  publication-title: Chem. Commun.
  doi: 10.1039/b402150a
  contributor:
    fullname: Almarsson Ö.
– volume: 4
  start-page: 881
  year: 2004
  ident: ref13/cit13
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg034172u
  contributor:
    fullname: Mazzotti M.
– volume: 95
  start-page: 215
  year: 1994
  ident: ref26/cit26
  publication-title: Fluid Phase Equilib.
  doi: 10.1016/0378-3812(94)80070-7
  contributor:
    fullname: Johannsen M.
– volume: 9
  start-page: 1621
  year: 2009
  ident: ref11/cit11
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg800764n
  contributor:
    fullname: Friščić T.
SSID ssj0007633
Score 2.3791513
Snippet Carbon dioxide has been extensively used as a green solvent medium for the crystallization of active pharmaceutical ingredients (APIs) by replacing harmful...
SourceID swepub
crossref
acs
SourceType Open Access Repository
Aggregation Database
Publisher
StartPage 3175
SubjectTerms Health Science
Hälsovetenskap
Title Insight into the Mechanisms of Cocrystallization of Pharmaceuticals in Supercritical Solvents
URI http://dx.doi.org/10.1021/acs.cgd.5b00200
https://urn.kb.se/resolve?urn=urn:nbn:se:ltu:diva-14547
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NT4MwFG90HtSDH1Pj_EoPM9EDCqXQclw2l3nQmKDGiyFtaXUJwjLg4H9vC2zZYpbotSm0ea_l_R7vvd8DoKtBMnX9ONYaIK6FqZIWFxxZnHCsEPeVU5WPjULy-EYHd4Ym53pFBB85t0xo4X_EN56xJ7b2zjcQ0TjBoKB-OP_o6mtS5dJ7qKLHdOcsPr9eYMyQyJfM0BJJaGVYhrv_2NIe2GnQI-zV6t4HazJtg83-rGlbG2wv8AsegPf7NDfONxynRQY11IMP0lT6jvOvHGYK9jMx_dbwMEmaakwz-PS5-Jc718_CsJzIqWiaIsAwS0ySZH4IXoZ3z_2R1fRTsJjr4MJSUklKmEAyYJwzLjCLKeamuNZmsYclIYFwuTKRWWULDdWYDBAPHI_ygDLhHoFWmqXyGEDD2yWJh4SDhDZvnArhc2bTOJDYpdzvgK4WUtTchzyqQt3IicygllzUSK4DrmZaiCY1u8bqqZe1luYTDTH2YPzai7RqoqQotRfjYXLyt5VPwZaGPl6deHsGWsW0lOdgPY_Li-pg_QDZm8q7
link.rule.ids 230,315,782,786,887,2769,27085,27933,27934,56747,56797
linkProvider American Chemical Society
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT8MwDI5gHAYHHgPEeOYwJC6Fvpsepz20iW1C6kBcUJWkKUwq7bRsB_49TtuNIYQE1yhNIzupP9f2Z4QaAJKJ5UYRaMCzNJvEQmOcmRrzmB2bzI2NvHysF3ijZ9LuKJocfVkLA5uQsJLMg_hf7ALGnRrjr9Gto8yKDk76luMCFFZgqBWsvr1wW_KUesfMWTKtFZnPjwWUNeLymzX6xhWa25fu3v93to92SyyJm4XyD9CGSGuo2lq2cKuhnTW2wUP00k-lcsXxJJ1nGIAfHgpV9zuR7xJnMW5lfPYBYDFJytpMNfjwtv7PW8KzOFhMxYyXLRJwkCUqZVIeocduZ9zqaWV3BY1ahj3XYhEL4lFuCp8yRhm3aURspkptdRo5tvA8n1ssVnHaWOcA3KjwTeYbDmE-odw6RpU0S8UJworFS3iOyQ2Tg7FjhHOXUZ1EvrAtwtw6aoCQwvJ2yDAPfJtGqAZBcmEpuTq6WSojnBZcG79PvS6UtZqoaLLbk6dmCOoJk_kCfBrH9k7_9uYrVO2Nh4Nw0B_dn6FtAEVOkZJ7jirz2UJcoE0ZLS7zs_YJCDzTKA
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS8MwEA86wY8HP6bi_MzDBF-q_Uib9HHsgw11DKbii5QkTXRQ27FsD_73Jm03NkQQX480DXe53l3v7ncA1LWTTLwgjrUEsGchIoXFOHMthhmSLgukk7ePdYe4_0pabQOTg-a9MPoQSu-k8iS-0epxLEuEAefO0Pl7fOsb02LrQH3DD3BoQq5Gc7j4_mqNycvqfTdHyvQWgD4_NjAWiasVi7SCF5rbmM7e_063D3ZLnxI2iktwANZEWgVbzfkotyrYWUIdPARvvVSZkByO0mkGtQMIH4Xp_x2pTwUzCZsZn3xppzFJyh5NQxx8LP_7VvpZOJyNxYSXoxLgMEtM6aQ6As-d9lOza5VTFizqOWhqSSEFwZS7IqSMUcYRjQlipuXWprGPBMYh95g0-Vppc-3AURG6LHR8wkJCuXcMKmmWihMADZqXwL7LHZdro8cI5wGjNolDgTzCghqoayZFpZaoKE-Au05kiJpzUcm5GriZCyQaF5gbvy-9LgS2WGjgslujl0akRRQl05mObXyET__25iuwOWh1oode__4MbGvfyC8qc89BZTqZiQuwruLZZX7dvgH45tWr
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Insight+into+the+Mechanisms+of+Cocrystallization+of+Pharmaceuticals+in+Supercritical+Solvents&rft.jtitle=Crystal+growth+%26+design&rft.au=Padrela%2C+Luis&rft.au=Rodrigues%2C+Miguel+A.&rft.au=Tiago%2C+Jo%C3%A3o&rft.au=Velaga%2C+Sitaram+P.&rft.date=2015-07-01&rft.issn=1528-7483&rft.eissn=1528-7505&rft.volume=15&rft.issue=7&rft.spage=3175&rft.epage=3181&rft_id=info:doi/10.1021%2Facs.cgd.5b00200&rft.externalDBID=n%2Fa&rft.externalDocID=10_1021_acs_cgd_5b00200
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-7483&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-7483&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-7483&client=summon